Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Karenitecin in Malignant Melanoma
NCT00062491Phase 2Completed
- Sponsor
- BioNumerik Pharmaceuticals
- Start
- May 2002
- Primary completion
- Jun 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of karenitecin in Malignant Melanoma (MM), sponsored by BioNumerik Pharmaceuticals. Primary endpoint: Overall Response. Started May 2002; status: completed.
02
Drugs
karenitecin
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT00062491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00062491.